|
What are your thoughts on this sort of technology? http://patft.uspto.gov/netacgi/nph-Parser?Sect2=PTO1&Sect2=H... Summary:
Cytotropic Heterogeneous Molecular Lipids (CHML) are used to treat patients with multiple cancers. Numerous studies have been conducted in cellular, animal, pre-clinical and clinical trials. Results showed that CHML, as a biological molecular missile, can easily penetrate through the target cancerous cells to perform programmed cancer cell death (cancer apoptosis). Furthermore, CHML has produced anti-cancer angiogenesis and induced immune function increase. CHML was used to treat 592 patients with cancers in clinical trials. Results confirmed the following advantages of CHML treatment: non-toxicity, high response rate, high quality of life, and high survival rate for these patients. The protocols include local injection, arterial drip and intravenous drip to treat cancers of liver, lung, skin, breast, brain glioma, colon and rectum, stomach, head and neck, leukemia, malignant lymphoma, sarcoma, malignant melanoma, myeloma, and metastasis cancers, etc. Response rates (CR+PR) were as follows: liver cancer 77%, lung cancer 68%, skin cancer 94%, breast cancer 83%, brain glioma 78%, colon and rectum cancer 80%, stomach cancer 50%, head and neck cancer 78%, leukemia 83%, malignant lymphoma 71%, sarcoma 43%, malignant melanoma 67%, and myeloma 50%. No (0) episodes of grade II or above adverse reactions were observed. |
I always look at "promising results" with skepticism, especially when the authors have a direct financial interest in the project.
To keep in mind: complete remissions and partial remissions are good, but they're "softer" outcomes. What we want to see is an impact on "harder" outcomes, mainly overall survival. Cause-specific survival is another good one.
We like to associate tumor shrinkage with better survival but it's not that simple (unfortunately). Do we kill people with our treatment? It shrinks the tumors, but for how long? Is the treatment convenient? How did they define "partial response"? What tool did they use? -- the list goes on.